Tirbanibulin (Klisyri®). HTA ID: 21054

Assessment Status Rapid Review Complete
HTA ID 21054
Drug Tirbanibulin
Brand Klisyri®
Indication For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.
Assessment Process
Rapid review commissioned 15/11/2021
Rapid review completed 30/11/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that tirbanibulin not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.